other material
confidence high
sentiment positive
materiality 0.65
Genprex wins Japanese and European patent grants for REQORSA combos; Acclaim-3 update
Genprex, Inc.
- Japanese Patent Office issued favorable Appeal Decision to grant patent for REQORSA + PD-L1 antibodies.
- European Patent Office granted patent for REQORSA + PD-1 antibodies to treat cancer.
- Acclaim-3 Phase 2 expansion: enrollment of first 25 patients for interim analysis expected by H1 2026; interim analysis in H2 2026.
- Phase 2 primary endpoint: 18-week progression-free survival rate; trial targets ~50 patients with ES-SCLC.